Peijia Medical's (HKG:9996) transcatheter aortic valve replacement system completed its first compassionate use treatment of the device in Hong Kong, according to a Monday filing with the Hong Kong Exchange.
The medical device company completed patient enrollment for the TaurusTrio system in January.
The device is indicated for symptomatic, severe aortic regurgitation, a heart valve disease.